CPT 0525U: 3D Predict™ Ovarian Chemotherapy Response Assay
CPT code 0525U designates a Proprietary Laboratory Analyses (PLA) test — the 3D Predict™ Ovarian assay from Kiyatec® Inc. — that uses three-dimensional spheroid cell culture to predict ovarian, fallopian, or peritoneal tumor response to a panel of 11 chemotherapeutic drugs. Nationally, PLA codes like 0525U matter because they identify single-source, manufacturer- or lab-specific diagnostics that can affect coverage policy, lab utilization, and precision oncology workflows.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, how the service is typically delivered in laboratory and outpatient oncology settings, and the implications for treatment planning in ovarian and related cancers. The publication outlines reimbursement and coverage considerations at a national level, summarizes common modifiers and administrative details, and situates the test within the broader landscape of companion and predictive oncology diagnostics.
This report is intended to inform billing, coding, and policy teams about the nature of CPT code 0525U, its clinical purpose, and the operational settings where the service is performed. Data not available in the input is noted where applicable.
Customize your policy alerts
Sign up for cpt 0525U policy alerts
Get alerted when payer policies referencing 0525U are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 0525U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the single commercial test 3D Predict™ Ovarian from Kiyatec® Inc. The assay uses 3D spheroid cell culture technology to evaluate how ovarian, fallopian, or peritoneal cancer cells respond to a panel of 11 chemotherapeutic agents, supporting personalized chemotherapy selection.
Service Type: Laboratory-based proprietary predictive chemotherapy response assay
Typical Site of Service: Clinical laboratory or specialty molecular diagnostics laboratory; sample collection typically occurs in outpatient oncology clinics or hospital outpatient settings